FP
Flagship Pioneering Portfolio holdings
AUM
$268M
This Quarter Return
-6.57%
1 Year Return
-54.4%
3 Year Return
-51.2%
5 Year Return
+66.7%
10 Year Return
–
AUM
$2.24B
AUM Growth
+$2.24B
(-13%)
Cap. Flow
-$377M
Cap. Flow
% of AUM
-16.84%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
11
New
–
Increased
–
Reduced
3
Closed
1
Top Buys
No buys this quarter
Top Sells
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Moderna
MRNA
$9.37B
| $1.57B | 69.88% | 12,886,743 | – | – |
|
2
Sana Biotechnology
SANA
$777M
| $198M | 8.85% | 33,290,018 -949,000 | -3% | -$5.66M |
|
|
OMGA
3
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
| $164M | 7.3% | 29,225,579 | – | – |
|
4
Seres Therapeutics
MCRB
$166M
| $111M | 4.94% | 23,117,045 | – | – |
|
5
Foghorn Therapeutics
FHTX
$286M
| $89.2M | 3.98% | 12,674,120 | – | – |
|
6
Denali Therapeutics
DNLI
$2.23B
| $77.3M | 3.45% | 2,619,968 | – | – |
|
|
SGTX
7
DELISTED
Sigilon Therapeutics, Inc. Common Stock
SGTX
| $18M | 0.8% | 797,720 -9,572,649 | -92% | -$215M |
|
|
EVLO
8
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
| $8.19M | 0.37% | 2,521,369 -47,905,959 | -95% | -$156M |
|
|
AXLA
9
DELISTED
Axcella Health Inc. Common Stock
AXLA
| $6.39M | 0.29% | 29,251,545 | – | – |
|
|
SYRS
10
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $3.13M | 0.14% | 993,848 | – | – |
|
|
CDAK
11
DELISTED
Codiak BioSciences, Inc. Common Stock
CDAK
| – | – | -3,540,636 | Closed | -$618K |
|